drugset

drugset / Trial / NCT00634452

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

NCT00634452 ↗

Phase 1 Completed 22 enrolled Bristol-Myers Squibb

NaSingle-groupOpen-labelTreatment

Summary

To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).

Timeline

Start: 2008-02
Primary completion: 2010-01
Completion: 2010-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDX-1401	Unknown	—	Intravenous

Indications